April 7 (Reuters) - Lexeo Therapeutics Inc LXEO.O:
LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1/2 DATA FOR LX2006 IN FRIEDREICH ATAXIA CARDIOMYOPATHY SUPPORTING ADVANCEMENT TO REGISTRATIONAL STUDY
LEXEO THERAPEUTICS INC: LX2006 GENERALLY WELL TOLERATED WITH NO SIGNS OF COMPLEMENT ACTIVATION OR OTHER IMMUNOGENICITY TO DATE
LEXEO THERAPEUTICS : PARTICIPANTS WITH ABNORMAL LEFT VENTRICULAR MASS INDEX AT BASELINE ACHIEVED 25% MEAN REDUCTION IN LVMI BY 12 MONTHS OR SOONER
LEXEO THERAPEUTICS : CLINICALLY MEANINGFUL IMPROVEMENTS IN MAJORITY OF PARTICIPANTS ACROSS CARDIAC BIOMARKERS & FUNCTIONAL MEASURES
Source text: ID:nGNX4F00MX
Further company coverage: LXEO.O
(((( Reuters.briefs@thomsonreuters.com ;));))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。